clinical development raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Some proteins never fold in cells at all except with the assistance of chaperones which either isolate individual proteins so that their folding is not interrupted by interactions with other proteins or help to unfold misfolded proteins, allowing them to refold into the correct native structure. This function is crucial to prevent the risk of precipitation into insoluble amorphous aggregates. The external factors involved in protein denaturation or disruption of the native state include temperature, external fields (electric, magnetic), molecular crowding, and even the limitation of space (i.e. confinement), which can have a big influence on the folding of proteins. High concentrations of solutes, extremes of pH, mechanical forces, and the presence of chemical denaturants can contribute to protein denaturation, as well. These individual factors are categorized together as stresses. Chaperones are shown to exist in increasing concentrations during times of cellular stress and help the proper folding of emerging proteins as well as denatured or misfolded ones. Under some conditions proteins will not fold into their biochemically functional forms. Temperatures above or below the range that cells tend to live in will cause thermally unstable proteins to unfold or denature (this is why boiling makes an egg white turn opaque).
In mountainous areas, they seek southerly slopes at lower elevations for forage and move to northerly and easterly slopes at higher elevations as summer progresses. The time that American black bears emerge from hibernation varies. Factors affecting this include temperature, flooding, and hunger. In southern areas, they may wake up in midwinter. Further north, they may not be seen until late March, April, or even early May. Altitude also has an effect. Bears at lower altitudes tend to emerge earlier. Mature males tend to come out earliest, followed by immature males and females, and lastly mothers with cubs. Mothers with yearling cubs are seen before those with newborns.
== Structure and superfamilies == RNA helicases are split into two main categories based on their ability to form oligomeric structures. Of the six superfamilies (SFs) that exist, SFs 1 and 2 do not form rings, whereas SFs 3, 4, 5, and 6 do. The first two superfamilies, usually found in eukaryotes, are composed of a structurally conserved core that is usually surrounded by large N- and C- terminal domains that function as RNA and DNA binding domains, protein binding domains, and other molecular specific functions. The function of these domains is extremely significant in cellular interaction by increasing specificity of recruitment of proteins by using structurally specific complexes and sequences within families. These two helicases are also made up of at least 12 structural motifs are positioned in specific sequences that vary between families but are usually highly conserved within the same family. SFs 3 through 6 form hexameric rings and are usually found in bacteria and viruses. Proteins of the superfamilies 3 and 4 are most similar to each other. However, SF4 contains a packaging motor named P4 that plays a role of packaging the RNA into a phage by first unwinding the structure and translocating the information into capsids. SF5 contains a Bacterial Rho factor that works to regulate transcription termination as well as removing RNA polymerase. SF6 contains a structure that works similarly to the Bacterial Rho factor but is different structurally.
Sources: en.wikipedia.org
White was married to his wife Edna for more than 40 years. He died unexpectedly on February 14, 1980, in Santa Barbara, California, where he had gone that day from his home in Palo Alto to deliver a lecture at the University of California. Several awards in the field of biochemistry have been named for White, including at Oakland University in Michigan, Wayne State University, George Washington University School of Medicine and the Gladstone Institutes. 1935 – Traveling Fellowship, American Physiological Society, for the XVth International Congress of Physiology (Leningrad and Moscow) 1938 – Eli Lilly Prize in Biochemistry 1960 – Distinguished Alumni Award, University of Denver 1967 – Sesquicentennial Alumni Award, University of Michigan 1969 – Borden Award, Association of American Medical Colleges 1959 – Doctor of Humane Letters, Yeshiva University 1975 – Doctor of Science, University of Denver
== Health and death == When Todd signed on to film Final Destination Bloodlines in 2023, he privately let the producers know that he had terminal stomach cancer. During filming in early 2024, they elected to allow Todd to improvise the last lines of his character Mr. Bludworth so he could give a proper goodbye to audiences: "Life is precious, enjoy every single second. You never know when ... Good luck". Todd died at his home in Marina del Rey, California, on November 6, 2024, at the age of 69. His cause of death was listed as stomach cancer. Both Final Destination Bloodlines and Indiana Jones and the Great Circle were dedicated to his memory. Insomniac Games intended to make a spin-off video game starring Venom after Todd played the character in Marvel's Spider-Man 2. However, the game was reportedly cancelled or placed on the backburner after his death. Both his co-stars Nadji Jeter (whom Todd affectionally called "nephew") and Yuri Lowenthal attended his funeral.
Iodine in food is absorbed by the body and preferentially concentrated in the thyroid where it is needed for the functioning of that gland. When 131I is present in high levels in the environment from radioactive fallout, it can be absorbed through contaminated food, and will also accumulate in the thyroid. As it decays, it may cause damage to the thyroid. The primary risk from exposure to 131I is an increased risk of radiation-induced cancer in later life. Other risks include the possibility of non-cancerous growths and thyroiditis. The risk of thyroid cancer in later life appears to diminish with increasing age at time of exposure. Most risk estimates are based on studies in which radiation exposures occurred in children or teenagers. When adults are exposed, it has been difficult for epidemiologists to detect a statistically significant difference in the rates of thyroid disease above that of a similar but otherwise-unexposed group. The risk can be mitigated by taking iodine supplements, raising the total amount of iodine in the body and, therefore, reducing uptake and retention in the face and chest and lowering the relative proportion of radioactive iodine. However, such supplements were not consistently distributed to the population living nearest to the Chernobyl nuclear power plant after the disaster, though they were widely distributed to children in Poland. Within the US, the highest 131I fallout doses occurred during the 1950s and early 1960s to children having consumed fresh milk from sources contaminated as the result of above-ground testing of nuclear weapons.
Sources: en.wikipedia.org
Professor John Joseph Murray, Professor of Child Dental Health, University of Newcastle. For services to Dental Health. Raymond Godfrey Owen, . For public service in Wales, especially to the Police. George Hubbard Makgill, The Viscount of Oxfuird, For political service. David John Parker, Consultant Cardiac Surgeon, St George's Hospital, London. For services to Medicine. Roderick Sayers Paul, lately Chairman, British Water. For services to the Water Industry and to Export. Professor John Pitkeathly Ian Percy, Chairman, Accounts Commission for Scotland. For services to Accounting and to Local Authorities. Rupert Perry, President and Chief Executive Officer, EMI Europe. For services to the Recording Industry. Anna Bridget Plowden. For conservation services to Museums. Christopher Bernard Poole. For political service. Andrew Popat. For political service. David Edwin Potter, Chairman and Chief Executive, Psion plc. For services to the Manufacturing Industry. Bernard Albert Price, County Clerk and Chief Executive, Staffordshire County Council. For services to Local Government. Colonel John Richard George Putnam, . For services to the Territorial Auxiliary and Volunteer Reserve Association in South East England. John Anthony Ransford, lately Honorary Secretary, Association of Directors of Social Services. For services to Social Work. Steven Geoffrey Redgrave, . For services to Rowing. Timothy John Rix. For services to Publishing. Dermot James Roaf. For political and public service. James Donald Robson, , Leader, Durham County Council. For services to Local Government.
Spironolactone may be more effective than birth-control pills in the treatment of acne, and the combination of spironolactone with a birth-control pill may have greater effectiveness for acne than either alone. In addition, some clinical research has found that flutamide is more effective than spironolactone in the treatment of acne. In one study, flutamide decreased acne scores by 80% within 3 months, whereas spironolactone decreased symptoms by only 40% in the same period. However, the use of flutamide for acne is limited by its liver toxicity. Bicalutamide is a potential alternative to flutamide for acne as well. Spironolactone can be considered as a first-line treatment for acne in those who have failed other standard treatments such as topical therapies and under certain other circumstances, although this is controversial due to the side effects of spironolactone and its teratogenicity. Insufficient clinical evidence exists to compare the effectiveness of spironolactone with other antiandrogens for female-pattern hair loss. The effectiveness of spironolactone in the treatment of both acne and hirsutism appears to be dose-dependent, with higher doses being more effective than lower doses. Higher doses also have greater side effects, such as menstrual irregularities.
=== ATP production during photosynthesis === In plants, ATP is synthesized in the thylakoid membrane of the chloroplast. The process is called photophosphorylation. The "machinery" is similar to that in mitochondria except that light energy is used to pump protons across a membrane to produce a proton-motive force. ATP synthase then ensues exactly as in oxidative phosphorylation. Some of the ATP produced in the chloroplasts is consumed in the Calvin cycle, which produces triose sugars.
Around this time, a coachbuilder company called PT. Marvia Graha Motor (owned by Marvy Apandi, the executive director of Indomobil Group) built around 50 units replica of Porsche 911 (964) based on MR90 hatchbacks. While retaining the original 1.4-litre engine, 5-speed manual gearbox, suspension and dashboard (later models has 964 dashboard replica), the body was made from fiberglass by using the 964 production tools from VW Group. At that time Indomobil had a trial by assembling two Porsche 964 and planned to build Porsche and Audi in Indonesia to compete with BMW and Mercedes-Benz. The plan was terminated because the production quality was below VW Group's standard.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.